Related Experiment Video
Updated: Aug 1, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Preclinical evaluation of lovastatin
J S MacDonald1, R J Gerson, D J Kornbrust
1Department of Safety Assessment, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486.
The American Journal of Cardiology
|November 11, 1988
Summary
High-dose lovastatin causes toxicity in animals by over-inhibiting HMG CoA reductase. However, this animal toxicity does not predict human risk at therapeutic doses due to mechanism-based effects.
Area of Science:
- Pharmacology
- Toxicology
- Biochemistry
Background:
- Lovastatin targets HMG CoA reductase, an enzyme crucial for cholesterol synthesis.
- High-dose lovastatin administration in animals results in a wide range of toxicities.
Purpose of the Study:
- To evaluate the relevance of animal toxicity findings to human safety.
- To determine if adverse effects observed in animals predict significant risks in humans.
Main Methods:
- Review of existing toxicological data from animal studies.
- Analysis of the biochemical mechanism underlying lovastatin-induced toxicity.
- Comparison of high-dose animal effects with therapeutic human dosage levels.
Main Results:
- Animal toxicities are linked to an exaggerated pharmacological effect of lovastatin.
- Clear no-effect doses were identified for observed toxicities in animals.
- Adverse effects are mechanism-based, directly related to mevalonate synthesis inhibition.
Conclusions:
- Animal toxicity findings at high doses do not indicate significant human risk.
- Mechanism-based toxicity suggests a low likelihood of adverse effects at therapeutic human doses.
- Extensive human safety data supports the low risk profile of lovastatin in humans.
Related Concept Videos
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...